Javascript verkar inte påslaget? - Vissa delar av Lunds universitets webbplats fungerar inte optimalt utan javascript, kontrollera din webbläsares inställningar.
Du är här

Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy

  • S. Mustjoki
  • Marja Ekblom
  • T. P. Arstila
  • I. Dybedal
  • P. K. Epling-Burnette
  • F. Guilhot
  • H. Hjorth-Hansen
  • M. Hoglund
  • P. Kovanen
  • T. Laurinolli
  • J. Liesveld
  • R. Paquette
  • J. Pinilla-Ibarz
  • A. Rauhala
  • N. Shah
  • B. Simonsson
  • M. Sinisalo
  • J. L. Steegmann
  • L. Stenke
  • K. Porkka
Publiceringsår: 2009
Språk: Engelska
Sidor: 1398-1405
Publikation/Tidskrift/Serie: Leukemia
Volym: 23
Nummer: 8
Dokumenttyp: Artikel i tidskrift
Förlag: Nature Publishing Group


Dasatinib, a broad-spectrum tyrosine kinase inhibitor (TKI), predominantly targets BCR-ABL and SRC oncoproteins and also inhibits off-target kinases, which may result in unexpected drug responses. We identified 22 patients with marked lymphoproliferation in blood while on dasatinib therapy. Clonality and immunophenotype were analyzed and related clinical information was collected. An abrupt lymphocytosis (peak count range 4-20 x 10(9)/l) with large granular lymphocyte (LGL) morphology was observed after a median of 3 months from the start of therapy and it persisted throughout the therapy. Fifteen patients had a cytotoxic T-cell and seven patients had an NK-cell phenotype. All T-cell expansions were clonal. Adverse effects, such as colitis and pleuritis, were common (18 of 22 patients) and were preceded by LGL lymphocytosis. Accumulation of identical cytotoxic T cells was also detected in pleural effusion and colon biopsy samples. Responses to dasatinib were good and included complete, unexpectedly long-lasting remissions in patients with advanced leukemia. In a phase II clinical study on 46 Philadelphia chromosome-positive acute lymphoblastic leukemia, patients with lymphocytosis had superior survival compared with patients without lymphocytosis. By inhibiting immunoregulatory kinases, dasatinib may induce a reversible state of aberrant immune reactivity associated with good clinical responses and a distinct adverse effect profile. Leukemia (2009) 23, 1398-1405; doi:10.1038/leu.2009.46; published online 19 March 2009


  • Cancer and Oncology
  • Ph plus leukemia
  • TKI therapy
  • immunomodulation
  • dasatinib


  • ISSN: 1476-5551

Box 117, 221 00 LUND
Telefon 046-222 00 00 (växel)
Telefax 046-222 47 20
lu [at] lu [dot] se

Fakturaadress: Box 188, 221 00 LUND
Organisationsnummer: 202100-3211
Om webbplatsen